Crystalline Piperazine Carboxylate Forms for Solubility and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The unpredictability and complexity in discovering and selecting solid forms of pharmaceutical compounds, such as (R)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate, affect their solubility, stability, and bioavailability, posing challenges in formulation and therapeutic efficacy.
Innovation Solution
The development of novel crystalline forms of (R)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate, characterized by specific X-ray diffraction patterns and thermal analysis, which are prepared through methods like solvent recrystallization and characterized for stability and solubility.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple polymorphic forms are discovered, then solubility and bioavailability can be improved, but the complexity of solid form selection and formulation increases
Solution Approach 1:
The patent segments the solid form selection process by identifying and characterizing distinct polymorphic forms (Forms I-VI) with unique XRPD patterns and properties. Each form is evaluated separately for solubility, stability, and manufacturability, allowing systematic selection rather than overwhelming complexity.
Solution Approach 2:
The patent applies parameter changes by modifying crystallization conditions (solvent type, temperature, pH, additives) to access different polymorphic forms. This enables control over which solid form is obtained, allowing optimization of solubility and bioavailability while managing formulation complexity through predictable form selection.
2Stability of the object's composition
If crystalline forms are developed to improve stability, then manufacturing and storage conditions become more controlled, but the difficulty of detecting and measuring appropriate solid forms increases
Solution Approach 1:
The patent employs X-ray powder diffraction (XRPD) as a characteristic 'fingerprint' method to detect and measure different crystalline forms. Each polymorph has a unique diffraction pattern that serves as an unambiguous identifier, making detection and measurement straightforward despite the complexity of multiple stable forms.
Solution Approach 2:
The patent replaces complex stability testing mechanisms with direct structural characterization using XRPD and DSC. Instead of relying on lengthy stability studies to infer form identity, the patent uses these analytical methods to directly identify and confirm the desired crystalline form, simplifying detection and measurement.
3Reliability
If novel crystalline forms are synthesized and characterized, then solubility and stability are enhanced, but the time and resources required for discovery and development increase
Solution Approach 1:
The patent applies preliminary action by systematically exploring multiple crystallization pathways and characterizing polymorphic forms early in the development process. By proactively identifying and selecting the most promising forms (Forms I-VI) with optimal solubility and stability profiles, the patent avoids time-consuming trial-and-error later in formulation development.
Solution Approach 2:
The patent uses computational modeling and predictive tools as intermediaries to guide the synthesis and characterization of crystalline forms. These tools help prioritize which polymorphs to investigate further, reducing the overall time and resources required for discovery by focusing efforts on the most promising candidates.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These crystalline forms enhance the stability and solubility of the compound, facilitating the development of effective pharmaceutical compositions for treating disorders related to MAGL and FAAH activity, including pain, neurological disorders, and cancer.
Implementation Method 1
prepared through methods like solvent recrystallization
Implementation Method 2
characterized by specific X-ray diffraction patterns
Implementation Method 3
characterized by specific X-ray diffraction patterns
Implementation Method 4
characterized by specific X-ray diffraction patterns and thermal analysis
Data Source
AI summary
Provided herein are crystalline forms of (R)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate. Pharmaceutical compositions comprising crystalline forms of (R)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate are also disclosed.